we are pleased to announce that the 8th Heidelberg Myeloma Workshop will take place in a virtual format on 16th and 17th of April, 2021. This biennial meeting will continue to focus on new developments in multiple myeloma and a panel of internationally renowned experts will discuss the range of current therapeutic approaches. The workshop has been organized by the Multiple Myeloma Division of the Department of Internal Medicine V at Heidelberg University Hospital and the National Center for Tumor Diseases, Heidelberg (NCT).
Recent years have seen myeloma patients benefit from more refined diagnostic criteria and a wider range of treatment options. In particular, immunotherapies such as CAR T-cell therapy have a high potential to improve myeloma therapy. Other immunotherapeutic treatments are based on bispecific antibodies and so-called antibody-drug conjugates. Both the earlier initiation of treatment and a greater appreciation of the importance of targeting sustained deep remissions offer new opportunities to further extend patient survival.
A precise delineation of the prognosis of different patient groups can be achieved by the detection of genetic alterations and characteristic clinical and molecular markers. Trendsetting are the methods of imaging and molecular medicine, which are combined within the framework of systems medicine and continuously improve our understanding of the disease.
The 8th Heidelberg Myeloma Workshop will start at 11.45 a.m. on Friday, the 16th of April, 2021. We hope that this program will be of interest to you and look forward to welcoming you at our virtual event.
Prof. Dr. Hartmut Goldschmidt
Prof. Dr. Marc-Steffen Raab
Dr. rer. nat. Niels Weinhold